A novel therapy called Emicizumab can reduce the incidence of bleeding episodes by 87 percent in patients with hemophilia A inhibitors, finds a Phase II clinical trial. Patients with hemophilia A -- caused by deficiency of coagulation factor VIII -- often experience excessive bleeding in the event of a cut or injury and require prophylactic treatment with intravenously administered factor VIII three times a week. However, repeated administration of clotting factor can increase the development of antibodies called inhibitors. These inhibitors attack and destroy the necessary factor that affects the treatment.
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer